Cargando…

Erythropoiesis stimulating agents: approaches to modulate activity

Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be r...

Descripción completa

Detalles Bibliográficos
Autor principal: Sinclair, Angus M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704234/
https://www.ncbi.nlm.nih.gov/pubmed/23847411
http://dx.doi.org/10.2147/BTT.S45971